Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.
about
Hypericin in the Light and in the Dark: Two Sides of the Same CoinSolvatochromic effects in the electronic absorption and nuclear magnetic resonance spectra of hypericin in organic solvents and in lipid bilayers.Clinically relevant safety issues associated with St. John's wort product labels.Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties.Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy?Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin.Reduction in hypericin-induced phototoxicity by Hypericum perforatum extracts and pure compounds.Molecular mechanisms of toxicity of important food-borne phytotoxins.Phototoxicity in human retinal pigment epithelial cells promoted by hypericin, a component of St. John's wort.A single-dose toxicity study on non-radioactive iodinated hypericin for a targeted anticancer therapy in mice.Retinal photodamage by endogenous and xenobiotic agents.Phototoxicity in human lens epithelial cells promoted by St. John's Wort.Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum.Lens alpha-crystallin and hypericin: a photophysical mechanism explains observed lens.Screening of selected plant extracts for in vitro inhibitory activity on human immunodeficiency virus.Traditional medicines, HIV, and related infections: workshop 2C.Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs.Analysis of selected constituents in methanolic extracts of Hypericum perforatum collected in different localities by capillary ITP-CZE.Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus.
P2860
Q26747362-130BEF3B-CC4B-489F-98FC-BF6BF4DDA8A5Q30642577-60C1203B-7B6A-4A8D-AC7A-5F0AD9F76374Q33352845-9A976747-4F4E-48A5-BF3F-B36246A6A48BQ33981422-1489FB4A-7062-480D-843D-97C7520C729AQ34093032-BD5F3518-2B41-48BC-B59A-48F8F9854746Q34259736-510CCD6C-CA23-412A-8F42-CF847965CCDEQ34562862-EDBE98B7-4F1A-45B4-AA0B-E3E645A0D1EDQ34585509-F0CF739D-30A0-4B4C-8D8E-E31B3C93104EQ35103698-A52F3785-4E84-48DD-AF55-B7E1FDA73327Q36001268-00D0D27A-689D-4618-BCE8-DE5140AB7F5EQ36166281-FE4E4ED4-8E23-4FE1-817E-D346A68357EAQ37727160-09393E9B-11CA-42C3-854D-CD18C3BF23D3Q38009850-D6BB10AA-0AD5-496D-A5F1-C62ADE0BD8F2Q40476479-6AA2363D-576A-4EB1-87F0-A5A8B4A81021Q42584889-EE146C71-F68B-4A85-9DB3-3A92F6CB5C5DQ43957580-729323B4-9399-4FEB-A6AE-C55841591809Q44141639-DDE0ADA9-F129-4710-AEF8-AB823269F348Q47310550-A75B9D56-9B4E-4640-A1B1-D3634024A4A7Q48286237-D843A6BA-6CEF-443F-A8DF-925A1191BF96Q52674651-450DD4F9-A4AA-45E5-96B1-143D713FBCFBQ54212657-9556C829-2353-40DD-86EE-A379818D0E61
P2860
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Phase I studies of hypericin, ...... s Group Protocols 150 and 258.
@ast
Phase I studies of hypericin, ...... s Group Protocols 150 and 258.
@en
type
label
Phase I studies of hypericin, ...... s Group Protocols 150 and 258.
@ast
Phase I studies of hypericin, ...... s Group Protocols 150 and 258.
@en
prefLabel
Phase I studies of hypericin, ...... s Group Protocols 150 and 258.
@ast
Phase I studies of hypericin, ...... s Group Protocols 150 and 258.
@en
P2093
P1476
Phase I studies of hypericin, ...... s Group Protocols 150 and 258.
@en
P2093
Crumpacker C
Holden-Wiltse J
McAuliffe V
Valentine FT
P304
P356
10.7326/0003-4819-130-6-199903160-00015
P407
P577
1999-03-01T00:00:00Z